ALEXANDRIA, Va., Sept. 30 -- United States Patent no. 12,429,486, issued on Sept. 30, was assigned to NX PHARMAGEN INC. (Lexington, Ky.).

"Use of Tenascin-C as an extracellular marker of tumor-derived microparticles" was invented by Alan M. Ezrin (Sarasota, Fla.) and Steven G. Griffiths (Moncton, Canada).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present disclosure provides methods for isolating tumor-derived microparticles from a subject for analysis, specifically by isolating Tenascin-C positive microparticles from a sample from the subject to obtain tumor-derived microparticles. Methods for determining the expression status of biomarkers in the tumor-derived microparticles and methods for determini...